Keyword: Sustiva

Bristol-Myers Squibb building

5. Sustiva

Bristol’s HIV med Sustiva first won approval in 1998 and is set to lose exclusivity in December,  according to the company’s 2016 10-K, making vulnerable a big chunk of U.S. sales.